Industry News
Inovio Pharmaceuticals Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine
May 09, 2011
Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV)... Read More
Study Indicates Guided Therapeutics' LuViva Advanced Cervical Scan Has Potential To Detect Disease Early And Reduce Unnecessary Biopsies For Women
May 04, 2011
As many as one million American women could avoid painful and unnecessary biopsies of the cervix and another estimated 170,000 could potentially be identified with cervical disease up to two years earlier, if technology developed by Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) was widely used, according to a presentation made by Dr. Leo B... Read More
HIV Drug Could Prevent Cervical Cancer
May 04, 2011
A widely used HIV drug could be used to prevent cervical cancer caused by infection with the human papilloma virus (HPV), say scientists. University of Manchester researchers, working with colleagues in Canada, have discovered how the antiviral drug lopinavir attacks HPV by switching on a natural viral defence system in infected cells... Read More
Distinguishing Between Primary Endometrial And Cervical Cancer Diagnosis Using MRI
May 03, 2011
MRI can determine if a patient has endometrial versus cervical cancer even when a biopsy can't make that distinction, according to a new study. Determining the primary site of a tumor helps determine appropriate cancer treatment... Read More
Guided Therapeutics To Unveil Cervical Disease Detection Technology New Design And Branding At ACOG And EUROGIN Meetings
Apr 28, 2011
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP), announced that it will present the new design and branding of its non-invasive and painless test for the early detection of cervical precancer at two upcoming international gynecology conferences. Additionally, attendees will be briefed on results of the pivotal clinical trial of the technology by two principal investigators... Read More
Current Long-Term Surveillance Strategy For Women Treated For Precancerous Cervical Lesions Effective For Preventing Cervical Cancer
Apr 27, 2011
Women who have been treated for precancerous cervical lesions face a similar 5-year risk of developing cervical cancer or recurrent disease to women in the general population after three consecutive normal cytological smears (Pap tests), and can return to population-based regular screening... Read More
Previous Page